- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01117064
Neuromodulation Therapy Device for the Treatment of Sleep Apnea
Study Overview
Status
Conditions
Detailed Description
Neuromodulation Therapy Device for the Treatment of Sleep Apnea
Obstructive sleep apnea (OSA) is a common public health problem with severe health consequences that substantially raises the risk of cardiovascular and cerebrovascular death. Continuous positive airway pressure (CPAP) is currently the most effective treatment option, yet up to half of patients fail to tolerate CPAP and require other approaches. Novel treatments offering alternatives to CPAP are thus sorely needed by those suffering from OSA. The Neuromodulation Therapy Device (NMTD) is a novel potential therapy for OSA. The main goal of our project is to evaluate the efficacy, tolerability, and safety of NMTD in patients with OSA.
Hypothesis 1 - The NMTD device is capable of reducing AHI.
OSA severity is indexed by apnea-hypopnea index (AHI), the number of apnea/hypopnea events occurring hourly during sleep. Our first aim is to determine NMTD's operating characteristics for treatment of OSA. The optimal duration of a detected apnea/hypopnea event before NMTD responds must first be determined. Additional adjustable features include sensitivity of respiratory event sensor, as well as pulse duration, frequency, and intensity of the delivered auditory tone. Since independent adjustment of each of the 4 parameters is not feasible, our screening analysis will test two variables at a time to identify which variables most effectively reduce AHI. This will allow for more practical titration during a therapeutic sleep study and more generalizable application of the device.
Hypothesis 2 - Modified NMTD is as effective and tolerable as CPAP in OSA treatment.
Once Aim 1 is complete and effective NMTD settings have been identified, we will initiate a Phase II NMTD trial to assess efficacy and tolerability. The primary outcome variable will be AHI reduction by NMTD compared with CPAP during a repeat polysomnogram (PSG). We will randomly assign previously titrated CPAP vs. NMTD to each subject then compare the resultant AHI between the two devices. Tolerability will also be assessed by sleep efficiency, arousal index, and sleep architecture. While auditory stimuli below 90 dB threshold should not adversely affect sleep architecture and quality,1 intermittent stimuli given during different sleep stages have not been previously assessed. Therefore, we will monitor NMTD's influence on sleep architecture, arousal index, and sleep efficiency compared to the same variables during CPAP use, allowing us to examine whether NMTD affects sleep quality. We will also assess patient preference in using CPAP versus NMTD.
Hypothesis 3 - NMTD will maintain efficacy with repeated use.
Given the brain's plasticity, it is unknown whether the brain may adapt to such repeated auditory stimuli. Constant auditory stimuli may lead to adaptation, resulting in the stimuli being "ignored." NMTD's stimuli, however, are less likely to lead to significant adaptation since they are intermittent and somewhat random, dependent on apneic or hypopneic events. Subjects will undergo two sequential nights of PSG with NMTD to evaluate if there is any stimulus-response extinction over time. In the future, when more devices are available, we will plan on long-term evaluations.
We propose to test this novel device in the treatment of OSA. This device, if successful, will substantially expand the treatment options for OSA by offering an effective alternative to CPAP with the potential for improved treatment compliance.
Plan:
This is a prospective study evaluating the efficacy of the NMTD in the treatment of OSA.
The study is divided into three consecutive phases, representing the three aims. If eligible, participants will be assigned to the phase that is currently being studied.
- One PSG, using the NMTD all night (32 participants)
- One PSG, split between the NMTD and standard CPAP therapy, randomized as to which is first (20 participants)
- Two consecutive PSGs using the NMTD all night (20 participants) to assess stimulus-response extinction over time (20 participants) All participants will complete a questionnaire about their experience with the device.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects 18 years or older
- Completed a comprehensive Sleep Medicine evaluation and a standard split-night polysomnogram
- Able to give informed consent
- Confirmed diagnosis of OSA
- Positive airway pressure device naive
Exclusion Criteria:
- Unsuccessful CPAP titration
- Inability to detect screening tone in either ear without the use of hearing aid
- Inability to tolerate a 37 dB tone
- Need for nocturnal oxygen or non-invasive positive pressure ventilation due to hypoventilation/hypercapnia
- Predominantly mixed or central apneas or those who develop complex sleep apnea during the PSG
- Neurologic disorders such as seizure disorder or narcolepsy
- Psychiatric disorders currently not under adequate control
- Need for nurse or other's assistance during the night due to problems of nocturnal confusion, delirium, or other conditions that would preclude the subject from wearing the device all night
- Pregnancy (will be tested)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: NMTD adjustment testing
We will determine effective NMTD device settings for reducing AHI.
|
Subjects will have an overnight PSG using CPAP (as previously titrated) for half of the night and NMTD the other half (this order will be randomized).
we will monitor NMTD's influence on Apnea Hypopnea Index (AHI), sleep architecture, arousal index, and sleep efficiency compared to the same variables during CPAP use
Subjects will have an overnight PSG using the NMTD.
This device detects reduced airflow via a polymer sensor.
When such event is detected, a short burst of sound is administered via earphones.
We will determine NMTD's operating characteristics for treatment of OSA.
The optimal duration of a detected apnea/hypopnea event before NMTD responds must first be determined.
Additional adjustable features include sensitivity of respiratory event sensor, as well as pulse duration, frequency, and intensity of the delivered auditory tone.
Since independent adjustment of each of the 4 parameters is not feasible, our screening analysis will test two variables at a time to identify which variables most effectively reduce AHI.
Subjects will undergo two sequential nights of PSG with NMTD to evaluate if there is any stimulus-response extinction over time.
|
Active Comparator: CPAP vs NMTD device
We will randomly assign previously titrated CPAP vs. NMTD to each subject then compare the resultant AHI between the two devices.
|
Subjects will have an overnight PSG using CPAP (as previously titrated) for half of the night and NMTD the other half (this order will be randomized).
we will monitor NMTD's influence on Apnea Hypopnea Index (AHI), sleep architecture, arousal index, and sleep efficiency compared to the same variables during CPAP use
Subjects will have an overnight PSG using the NMTD.
This device detects reduced airflow via a polymer sensor.
When such event is detected, a short burst of sound is administered via earphones.
We will determine NMTD's operating characteristics for treatment of OSA.
The optimal duration of a detected apnea/hypopnea event before NMTD responds must first be determined.
Additional adjustable features include sensitivity of respiratory event sensor, as well as pulse duration, frequency, and intensity of the delivered auditory tone.
Since independent adjustment of each of the 4 parameters is not feasible, our screening analysis will test two variables at a time to identify which variables most effectively reduce AHI.
Subjects will undergo two sequential nights of PSG with NMTD to evaluate if there is any stimulus-response extinction over time.
|
Active Comparator: NMTD efficacy and tolerability
Subjects will undergo two sequential nights of PSG with NMTD to evaluate if there is any stimulus-response extinction over time.
|
Subjects will have an overnight PSG using CPAP (as previously titrated) for half of the night and NMTD the other half (this order will be randomized).
we will monitor NMTD's influence on Apnea Hypopnea Index (AHI), sleep architecture, arousal index, and sleep efficiency compared to the same variables during CPAP use
Subjects will have an overnight PSG using the NMTD.
This device detects reduced airflow via a polymer sensor.
When such event is detected, a short burst of sound is administered via earphones.
We will determine NMTD's operating characteristics for treatment of OSA.
The optimal duration of a detected apnea/hypopnea event before NMTD responds must first be determined.
Additional adjustable features include sensitivity of respiratory event sensor, as well as pulse duration, frequency, and intensity of the delivered auditory tone.
Since independent adjustment of each of the 4 parameters is not feasible, our screening analysis will test two variables at a time to identify which variables most effectively reduce AHI.
Subjects will undergo two sequential nights of PSG with NMTD to evaluate if there is any stimulus-response extinction over time.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
We will determine effective device settings on the Neuromodulation Therapy Device (NMTD).
Time Frame: First year
|
First year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
We will compare the modified NMTD's efficacy and tolerability to that of CPAP in treating OSA.
Time Frame: Second year
|
Second year
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: John G. Park, M.D., Mayo Clinic
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 09-006804
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obstructive Sleep Apnea
-
LivaNovaActive, not recruitingApnea | Obstructive Sleep Apnea | OSA | Apnea, Obstructive | Apnea+Hypopnea | Apnea, Obstructive Sleep | Hypopnea, SleepUnited States
-
Mauro ManconiCompletedObstructive Sleep Apnea Syndrome | Sleep Apnea, Obstructive | Obstructive Sleep Apnea | OSA | Apnea, Obstructive | OSAHSwitzerland
-
University of California, Los AngelesRecruiting
-
Brigham and Women's HospitalCompletedObstructive Sleep Apnea (OSA)United States
-
ApnimedCompletedOSA - Obstructive Sleep ApneaUnited States
-
ResMedCompletedObstructive Sleep Apnea (OSA)United States, Australia
-
State Budgetary Healthcare Institution, National...RecruitingObstructive Sleep Apnea | Obstructive Sleep Apnea-hypopnea | Obstructive Sleep Apnea-hypopnea SyndromeRussian Federation
-
The Hospital for Sick ChildrenCompleted
-
Cryosa, Inc.Active, not recruitingObstructive Sleep Apnea of AdultPanama, Paraguay
Clinical Trials on Neuromodulation Therapy Device (NMTD)
-
Ziv HealthCare Ltd.RecruitingParoxysmal Atrial FibrillationIsrael
-
University of MichiganUS Department of Veterans AffairsRecruitingParkinson DiseaseUnited States
-
University of OklahomaNational Institute on Aging (NIA)Recruiting
-
Theranova, L.L.C.CompletedOveractive BladderUnited States
-
Icahn School of Medicine at Mount SinaiTivic Health SystemsRecruiting
-
Centre for Addiction and Mental HealthScion NeuroStimRecruitingSchizophrenia | AnosognosiaCanada
-
TriHealth Inc.TerminatedUrinary Urge IncontinenceUnited States
-
Rhode Island HospitalBrown University; US Department of Veterans Affairs; Boston Scientific Corporation and other collaboratorsRecruiting
-
University of OklahomaRecruitingLymphoma | Breast CancerUnited States
-
University of Las Palmas de Gran CanariaUniversity of Alcala; Alfonso X El Sabio University; University Pontifical of...Completed